Table 3.

Evaluation of the Potential Interaction of Fixed‐Dose Combination of CaD With Sex, Age, and Baseline Cardiovascular Risk on the Risk of Nonfatal Ischemic Stroke

Current Use of CaD	Cases (%) n=2690	Controls (%) n=19 538	Nonadjusted ORa (95% CI)	Adjusted ORb (95% CI)
Sex
Male	11 (0.78)	92 (0.90)	0.87 (0.47–1.64)	0.86 (0.44–1.65)
Female	76 (5.91)	651 (7.01)	0.83 (0.65–1.06)	0.86 (0.67–1.12) Test for interaction, P=1.000
Age
<70 y	16 (1.75)	154 (2.30)	0.75 (0.44–1.27)	0.76 (0.43–1.32)
≥70 y	71 (4.00)	589 (4.59)	0.85 (0.66–1.10)	0.87 (0.67–1.13) Test for interaction, P=0.668
Cardiovascular risk
Low‐intermediate	58 (3.96)	572 (4.10)	0.96 (0.72–1.27)	0.92 (0.69–1.23)
High	29 (2.37)	171 (3.06)	0.76 (0.51–1.14)	0.73 (0.48–1.10) Test for interaction, P=0.370

CaD indicates calcium supplements with vitamin D; CI, confidence interval; OR, odds ratio.

^aAdjusted only for matching factors (age, sex, and calendar year).

^bAdjusted for matching factors and for the variables described in Methods and Table 1.